Sensorion (ALSEN) investor relations material

Strategic vision and leadership

• Aims to enable people with inner ear hearing disorders to live with unlimited connections, addressing a major unmet clinical need affecting 1.5 billion globally.

• Employs a modality-agnostic approach, leveraging gene therapy and small molecules for multiple indications.

• Supported by an experienced leadership team, board, and scientific advisory board with deep expertise in biotech and hearing science.

• Backed by leading life sciences investors and exclusive global partnerships.

Pipeline and clinical programs

• SENS-601 gene therapy targets GJB2-related hearing loss, the most common cause of genetic deafness, with three forms: congenital, childhood, and early adult onset.

• SENS-601 demonstrates efficient, targeted delivery and functional restoration in preclinical models, with strong safety and efficacy data in mice and non-human primates.

• SENS-601 clinical development is advancing, with CTA filings in Canada and France and US IND planned by end of 2026.

• SENS-401, a first-in-class small molecule, is in clinical development for hearing preservation and prevention across three indications: cochlear implantation, cisplatin-induced ototoxicity, and sudden sensorineural hearing loss.

Clinical results and impact

• SENS-401 shows positive Phase 2 results in sudden sensorineural hearing loss, with 50% of treated patients achieving complete hearing recovery at Day 84, statistically superior to placebo.

• In cochlear implantation, SENS-401 achieves complete hearing preservation in 40% of treated patients at 6 weeks post-implant, with effects maintained after discontinuation.

• For cisplatin-induced ototoxicity, SENS-401 is safe and shows a trend toward otoprotective effect in patients with high cumulative cisplatin exposure.